Donald M. Berwick, MD, of CMS talks about what is now being covered for preventive care under the Affordable Care Act and where you can find more information. Government Perspectives on Healthcare
Category: News
New Test To Screen For Glaucoma Damage
A recent paper published in the Journal of Glaucoma shows a new visual evoked potential (VEP) technique to be a fast, objective method to screen for functional damage in glaucomatous eyes. The technique, called short duration transient VEP (SD-tVEP), s…
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Santen Announces The Initiation Of A Multinational Phase III Program Evaluating Sirolimus (DE-109) For The Treatment Of Non Infectious Posterior Uveitis
Santen Inc., announced the initiation of a global Phase 3 clinical study evaluating its investigational drug sirolimus (DE‐109) for the treatment of noninfectious posterior uveitis.
Difluprednate: A Novel Steroid for the Eye
Featured Article
FDA Plans to Extend Its Global Regulatory Reach
The FDA’s new strategy calls for it to evolve into a global agency that can work anywhere in the world. Medscape Medical News
Truly Portable Imager Produces Still And Video Images Of The Eye
Mentor, Ohio (June 16, 2011) – For convenient ocular imaging in any setting, Volk Optical’s new truly portable Pictor digital device enables ophthalmic imaging not possible with traditional fixed systems. The Pictor delivers high resolution images of t…
U.S. Advisers Back Regeneron Eye Drug
A new eye medicine from Regeneron Pharmaceuticals Inc and Bayer AG is safe and effective for treating a common cause of vision loss, a panel of U.S. experts said on Friday.
Dense Brunescent Cataracts Present Surgical Challenges
Among the most difficult cases for phacoemulsification is the dense brunescent cataract. Due to the increased nuclear density, the cataract surgery requires more effort, energy and attention to successfully complete. The patients are at a higher risk f…
Severe Complications From Cataract Surgery Decline
Serious, potentially blinding complications from cataract eye surgery are uncommon, and have been declining since the 1990s, a new U.S. study finds.
DRY EYE: AWARD WINNING TECHNOLOGY SOLVES DILEMMA FOR PATIENTS Ardeo HealthT Licenses New Dry Eye Therapy From Novagali Pharma
Suwanee, GA, USA (June 15, 2011) – Ardeo Health, LLC, a biopharmaceutical development and licensing company, announced today that it has reached an agreement with Novagali Pharma S.A. of Evry, France to license Novagali’s novel Nova23041 dry eye therap…
$3 Million Award To Develop Gene, Stem Cell Therapies For Common Eye Complication Of Diabetes
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that ca…
Regeneron Announces EYLEA™ (aflibercept Ophthalmic Solution) Receives Unanimous Recommendation For Approval For Treatment Of Wet AMD From FDA
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S…
ACT Announces First Patients Enrolled In Two Clinical Trials Using Embryonic Stem Cells To Treat Stargardt’s Disease
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular…
ACOs: Shared Savings and Improved Care, Says Don Berwick
Donald M. Berwick, MD, MPP, of CMS describes the structure of accountable care organizations and how they are designed to improve patient care. Government Perspectives on Healthcare
VEGF Trap-Eye For Wet Age-related Macular Degeneration Unanimously Approved By FDA Panel
VEGF Trap-Eye, used for the treatment of the neovascular form of age-related macular degeneration (wet AMD), a condition that can lead to blindness, has been approved by a 10 to 0 FDA Panel vote. The treatment is approved for administration every other…
Regeneron Announces EYLEA (aflibercept Ophthalmic Solution) Receives Unanimous Recommendation For Approval For Treatment Of Wet AMD From FDA Advisory Committee
Regeneron Pharmaceuticals, Inc. today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted unanimously to recommend that the FDA approve EYLEA, also known as VEGF Trap-Eye, for…
Sight Restored After 55 Years
Surgery has restored sight in the eye of a man who for 55 years had a detached retina that left him blind in his right eye after it was hit by a stone when he was 8 years old…
Cedars-Sinai receives National Eye Institute grant to develop gene therapy for corneal disease
Cedars-Sinai stem cell researchers investigating ways to prevent eye problems in diabetic patients have been awarded a $3 million grant from the National Eye Institute to develop gene therapy in corneal stem cells to alleviate damage to corneas that ca…